Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. - Wikidata - thesis-toulmin - TriplyDB

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

http://www.wikidata.org/entity/Q35321191

about

Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis Targeting Homeostatic T Cell Proliferation to Control Beta-Cell Autoimmunity Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells Inducing and Administering Tregs to Treat Human Disease Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience Targeting the trimolecular complex Type 1 diabetes Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease Concise review: pancreas regeneration: recent advances and perspectives Immunotherapy in autoimmune type 1 diabetes Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case Determining disease intervention strategies using spatially resolved simulations Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report The cell cycle as a brake for β-cell regeneration from embryonic stem cells Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Immune therapy in type 1 diabetes mellitus Type 1 diabetes: translating mechanistic observations into effective clinical outcomes Agent-Based Modeling in Systems Pharmacology The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes.Recommendations for the definition of clinical responder in insulin preservation studies Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes Induced CD8+FoxP3+ Treg cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane tumor necrosis factor α and CD86.Clinical & immunological profile of newly diagnosed patients with youth onset diabetes mellitus.Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice.Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Type 1 diabetes: A predictable disease.Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation.Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease.The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.

P2860

Q26748676-5CA6F48B-A213-49AC-BA6B-68AC6C88E253 Q26764999-CB5EF41F-BFE4-4DB4-8528-B63DDC5230D5 Q26772699-75894AA8-D5F9-4AA6-8F5E-32B6605314B5 Q26772723-4604088E-0F7D-46FD-823E-E802FC711989 Q26850621-30ECEBE3-E626-4F31-BC76-045807FA909A Q26864985-D6E0DC04-C182-48E4-BB66-8504E8F6DF7C Q27000491-04A9F0B5-14AE-49CE-8BD3-E45A6AF3B72A Q27008837-2CF6698E-11C1-4995-A8D6-DF86306B146D Q27013646-BBEE2B9B-D255-4B41-BAA6-333014774B64 Q27025619-40E02B3D-CD52-4996-A4C7-05CA6C35263A Q27028100-5299EE84-D455-455F-9547-EB850DC07B49 Q27301846-32992CD3-8356-4440-8C05-3D36231CBD44 Q27687598-12226D55-93B0-4DDF-A94A-8EB0839D379E Q28076123-38EB4110-DE7C-4530-B332-DF18BD099A30 Q28081034-69BDEAA9-F516-4083-9F2B-E406B2E1F6C1 Q28282846-A9705F4A-ED10-4A8C-AE14-253818A29C6B Q28287737-6338DEE6-5464-459C-B948-87748D45F7B0 Q28602444-38D00240-539D-4D43-BE5B-C2D5312ED84D Q33559343-C02CD32D-C81B-43C2-979C-A0BE0310D41A Q33639743-CA5094CB-6DD0-47E2-9278-0EB314C9A9DD Q33739020-B9A0E388-D33F-4109-99D9-C11AD8DF9DCF Q34077400-83FD39DB-336E-47DC-92BD-15440E51F8AA Q34318993-1E2A9758-0E3F-4D66-A741-A0981FAEAFA0 Q34375578-DED70439-1FD3-4BE5-A96E-CF2D2738A276 Q34393377-4DF15E55-A135-4140-8132-DA7B02E4551B Q34427172-C420FDF6-4601-40A9-B138-2825A168129E Q34590813-F41D82CD-625D-48C9-86C6-FCA18ABCA9F1 Q34796651-94379A15-E99D-4068-8092-3E385F88CEBE Q35035148-437DC244-43F2-4F6D-953E-06A82F177083 Q35205110-CE12D5F9-D16D-49F3-8797-77D367DB9985 Q35207904-DBFFAE01-36E4-4838-96F7-69AB4DC9D926 Q35360844-591E064F-455D-4824-B35F-40AB6B4057FB Q35437721-1788EB91-D99B-438A-8AA3-B586A74D5251 Q35612451-8F511434-FF2E-408C-8D7D-9EB7CE5E3320 Q35630698-513FB2FF-53E5-45C8-AEA7-583544EEB552 Q35787117-BB265983-3746-4457-81FF-4E3CE3A93D83 Q35897436-008546A2-F3E4-478F-BAE2-EA483F810308 Q35904021-50F5F8B2-6CD7-4E59-A87D-221F57D3C81F Q35913697-1B7610F9-BE24-41E4-BC68-A1EF0D5198E7 Q35976614-B9EA9D3C-B806-43CB-9EEF-B35A1337EF15

P2860

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

http://www.wikidata.org/entity/Q35321191

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Teplizumab for treatment of ty ...... sed, placebo-controlled trial.

@ast

Teplizumab for treatment of ty ...... sed, placebo-controlled trial.

@en

type

label

Teplizumab for treatment of ty ...... sed, placebo-controlled trial.

@ast

Teplizumab for treatment of ty ...... sed, placebo-controlled trial.

@en

prefLabel

Teplizumab for treatment of ty ...... sed, placebo-controlled trial.

@ast

Teplizumab for treatment of ty ...... sed, placebo-controlled trial.

@en

P1433

Q35321191-CCDFF571-F826-4D1B-980E-7ED61E138611

P1476

Q35321191-C6D4ED7D-4666-408D-AF61-8B360DF579CD

P2093

Q35321191-069F478F-FBB5-4BB4-9E69-798051DDB33A

Q35321191-197D2F3D-B569-4606-BAB7-A5CA31CA8B93

Q35321191-1F90B34F-F8AB-47C8-874E-953952559276

Q35321191-1F9DDB97-17F0-4974-BC1C-1773EFF5E2B7

Q35321191-301415ED-3CD6-41B6-865A-3928A5DFB286

Q35321191-3148841D-8254-4E17-9299-28D4D99D631A

Q35321191-5BCBFCF6-9205-4804-B111-8C09A483F224

Q35321191-61FAFB22-2BC6-4C99-9660-E83F0A3BC786

Q35321191-644DEB04-DEBA-4485-AB9D-D0B6AB66E60E

Q35321191-6D81F358-933D-4134-AB07-A2A4D4D2FE43

P2860

Q35321191-0F32807C-B14A-43F5-B94F-F0BB9F2ECDC8

Q35321191-40BA8815-AB8F-4D40-9B83-F2DCC211FA2C

Q35321191-4FCB3B62-6FC6-4646-9B9B-7B8A6C9E3478

Q35321191-5086A44E-A93D-4A59-BC40-53656F4275A0

Q35321191-5174BD09-46D2-424D-9EF0-E7983C558A8C

Q35321191-653B2C93-A860-47EF-95E6-6D624DD95B76

Q35321191-6F7A75E3-6CDF-4089-A278-A403EFBEF616

Q35321191-8152A80A-52E5-4F03-9ADC-7F0DFBCA175B

Q35321191-C02C3033-5959-45F5-B2AE-A683F577832E

Q35321191-D0BD1AAF-F361-40FB-822D-87368A263D0D

P304

Q35321191-395C8206-DF9A-4C9D-89B7-0CBAA6F5F205

P31

Q35321191-630FE498-9256-4F86-BBDD-4395A0A72989

P356

Q35321191-BA0EE95A-342C-476C-BA6B-A362360CED2A

P407

Q35321191-0EA9DEBF-864F-4C09-A5D4-12B0FC51DA17

P433

Q35321191-D2533B76-4E26-42C8-8AB0-59A30A98F04C

P478

Q35321191-72A255CA-A630-4B65-BE48-940875BC4ADE

P50

Q35321191-A1D715F2-64E3-4151-B1C6-25181D6D4D27

Q35321191-A9A5C4DA-C517-450F-AE62-5365973C0643

P577

Q35321191-DC2F9489-0690-4484-B833-87F74D450255

P698

Q35321191-F98FF8F3-CA87-468D-A42C-E808EA0F9D91

P921

Q35321191-0A2F17F6-78CB-40A7-9009-861E322518C0

Q35321191-1891EF62-B20B-4AA6-A161-D229B5B3B317

P932

Q35321191-DBCA6E39-C117-4783-95F6-F9549D6B2743

P356

S0140-6736(11)60931-8

P1433

P1476

Teplizumab for treatment of ty ...... sed, placebo-controlled trial.

@en

P2093

Anastasia G Daifotis

http://www.w3.org/2001/XMLSchema#string

Bruce Bode

http://www.w3.org/2001/XMLSchema#string

Christopher Holland

http://www.w3.org/2001/XMLSchema#string

David Carlin

http://www.w3.org/2001/XMLSchema#string

Ezio Bonvini

http://www.w3.org/2001/XMLSchema#string

Jack Wahlen

http://www.w3.org/2001/XMLSchema#string

Karen L King

http://www.w3.org/2001/XMLSchema#string

Kathryn E Stein

http://www.w3.org/2001/XMLSchema#string

Kevan C Herold

http://www.w3.org/2001/XMLSchema#string

Nicole Sherry

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Immunotherapy of type 1 diabetes: where are we and where should we be going?

Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

GAD treatment and insulin secretion in recent-onset type 1 diabetes.

Immunotherapeutic agents in type 1 diabetes: a systematic review and meta-analysis of randomized trials.

Type 1 diabetes: etiology, immunology, and therapeutic strategies.

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.

P304

487-497

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(11)60931-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

9790

http://www.w3.org/2001/XMLSchema#string

P478

378

http://www.w3.org/2001/XMLSchema#string

P50

Johnny Ludvigsson

P577

2011-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21719095

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3191495

http://www.w3.org/2001/XMLSchema#string